Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Report Third Quarter Financial Results on October 28, 2025 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025 to...

Key Takeaway: Alkermes plc will host a conference call on October 28, 2025, to discuss its third quarter financial results. The call will be accessible via a dedicated phone line and webcast, with a replay available shortly after the event. Alkermes is focused on developing treatments for various neurological disorders.
Price reaction · baseline $30.26 (2025-10-17 close) · 1 other ALKS headline(s) in the window, move may be shared
day 0 close · peak
+2.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes is set to report its third quarter financial results.
  • The company continues to develop innovative medicines in neuroscience.
  • Alkermes has a diverse portfolio of products and a strong pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

DUBLIN , Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025 to discuss the company's third quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc (Nasdaq: ALKS ), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com .

Frequently Asked Questions

When will Alkermes report its Q3 financial results?

Alkermes will report its Q3 financial results on October 28, 2025.

How can I access the Alkermes conference call?

The conference call can be accessed by dialing +1 877 407 2988 for U.S. callers.

Is there a replay available for the conference call?

Yes, a replay of the webcast will be available approximately two hours after the event.

What is Alkermes' focus in biopharmaceuticals?

Alkermes focuses on developing innovative medicines in the field of neuroscience.

Last updated: Oct 20, 2025